NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Research and Development Expense (TTM): 118.04M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 118.04M |
| September 30, 2023 | 142.87M |
| June 30, 2023 | 166.04M |
| March 31, 2023 | 179.12M |
| December 31, 2022 | 181.07M |
| September 30, 2022 | 173.07M |
| June 30, 2022 | 165.68M |
| March 31, 2022 | 163.82M |
| December 31, 2021 | 161.71M |
| September 30, 2021 | 163.04M |
| June 30, 2021 | 171.31M |
| Date | Value |
|---|---|
| March 31, 2021 | 166.23M |
| December 31, 2020 | 163.97M |
| September 30, 2020 | 165.87M |
| June 30, 2020 | 147.84M |
| March 31, 2020 | 138.16M |
| December 31, 2019 | 129.25M |
| September 30, 2019 | 116.24M |
| June 30, 2019 | 111.76M |
| March 31, 2019 | 105.79M |
| December 31, 2018 | 95.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
111.76M
Minimum
Jun 2019
181.07M
Maximum
Dec 2022
153.95M
Average
163.82M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Catalent Inc | -- |
| AIM ImmunoTech Inc | 10.84M |
| Perspective Therapeutics Inc | 24.91M |
| Protalix BioTherapeutics Inc | 14.13M |
| Armata Pharmaceuticals Inc | 32.18M |